BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HuDS6-DM4: Phase I started

sanofi-aventis began an open-label, dose-escalation Phase I trial to evaluate IV SAR566658 administered every 21 days in 80 patients with DS6-positive solid tumors. The...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >